Rifaximin
-
Rifaximin
structure -
-
CAS No:
80621-81-4
-
Formula:
C43H51N3O11
-
Chemical Name:
Rifaximin
-
Synonyms:
2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-;2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,[2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]-;(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione;L 105;Rifamycin L 105SV;L 105SV;Rifaximin;Rifamycin L 105;L 105 (ansamacrolide antibiotic);refaximin;Xifaxan;Normix;Xifaxanta;(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23,25-Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-acetate;126334-60-9;88747-56-2;1229193-76-3
- Categories:
-
CAS No:
Description
Rifaximin(Xifaxan) is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity.IC50 Value:Target: RNA polymerase; antibacterialRifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used in the treatment of traveler's diarrhea and hepatic encephalopat
Rifaximin is a nonabsorbable antibiotic that is used as treatment and prevention of travelers’ diarrhea and, in higher doses, for prevention of hepatic encephalopathy in patients with advanced liver disease and to treat diarrhea in patients with irritable bowel syndrome. Rifaximin has minimal oral absorption and has not been implicated in causing liver test abnormalities or clinically apparent liver injury.|A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.
Rifaximin Basic Attributes
785.88
785.88
1308068-626-2
DTXSID7045998
A - Alimentary tract and metabolism|D - Dermatologicals
Characteristics
198
6.29580
dark orange
1.4±0.1 g/cm3
200-205 °C (decomp)
1.634
ethanol: soluble1mg/mL
0-6°C
LD50 orally in rats: >2000 mg/kg (Borelli, Bertoli)
Safety Information
NONH for all modes of transport
2
KD1576000
|Warning|H312 (76.92%): Harmful in contact with skin [Warning Acute toxicity, dermal]|P201, P202, P261, P271, P280, P281, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 17 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Toxicity
Despite widespread use, there is little evidence that rifaximin when given orally causes liver injury, either in the form of serum enzyme elevations or clinically apparent liver disease.
Drug Information
Rifaximin is a nonabsorbable antibiotic that is used as treatment and prevention of travelers’ diarrhea and, in higher doses, for prevention of hepatic encephalopathy in patients with advanced liver disease and to treat diarrhea in patients with irritable bowel syndrome. Rifaximin has minimal oral absorption and has not been implicated in causing liver test abnormalities or clinically apparent liver injury.
Antiinfective Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)|Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
Rifaximin Use and Manufacturing
Non-absorbable semisynthetic Rifamycin antibiotic
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:785.9
XLogP3:6.9
Hydrogen Bond Donor Count:5
Hydrogen Bond Acceptor Count:12
Rotatable Bond Count:3
Exact Mass:785.35235945
Monoisotopic Mass:785.35235945
Topological Polar Surface Area:198
Heavy Atom Count:57
Complexity:1590
Defined Atom Stereocenter Count:9
Undefined Bond Stereocenter Count:3
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Drug Function and Efficacy
This product is a derivative of rifamycin and is the first non-aminoglycoside intestinal antibiotic. This product has a strong effect and a broad antibacterial spectrum. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. This product has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. When using this product, there is no need to use intestinal antispasmodics (such as lopramamide, etc.) or intestinal adsorbents (such as white clay, pectin, etc.). This product acts quickly, and diarrhea will no longer occur after 2 days, and abdominal cramps, headaches, nausea, and vomiting symptoms will disappear quickly. This product is not absorbed and maintains extremely high concentrations in the intestine, but does not exist in other organs. Features superior to neomycin, streptomycin and other aminoglycoside antibiotics: ① This product does not damage hearing function; ② It does not cause renal damage; ③ Parasitic normal flora, especially non-pathogenic enteric bacteria Escherichia coli, quickly relocate to the intestines to avoid repeated infection; ④ Intestinal mucosal inflammation may tend to disappear. Mucosal inflammation is a contraindication to the use of topical aminoglycosides, because the inflammation may be aggravated after medication.
Registered Holders
-
CHEMECA DRUGS PRIVATE LTD
Active
United States
-
OPTIMUS DRUGS PRIVATE LTD
Active
United States
-
RAKS PHARMA PVT LTD
Active
United States
Recommended Suppliers of Rifaximin
-
CN
3 YRS
Business licensedTrader Supplier of vitaminInquiryCAS No.: 80621-81-4Grade: Food gradeContent: 99% -
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
CN
7 YRS
Business licensed Certified factoryManufactory Supplier of chemicals -
CN
5 YRS
Business licensedTrader Supplier of Peptides,Chemicals,API,AdditivesInquiryCAS No.: 80621-81-4Grade: Pharmaceutical GradeContent: 99% -
CN
3 YRS
Business licensedTrader Supplier of olive leaf extract,ginger extract,ginseng extract,Black garlic extract,Echinacea purpurea extract,Horse Chestnut Extract,Pueraria extract,Andrographis Extract,citrus aurantium extract,quercetin,Rutin,chlorogenic acid,Curcumin,ApigeninInquiryCAS No.: 80621-81-4Grade: Pharmaceutical GradeContent: 99.9%
Learn More Other Chemicals
-
Dehydro RifaxiMin
80621-76-7
-
Oseltamivir phosphate
204255-11-8
-
Imidazole salicylate
36364-49-5
-
5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6,7-dihydro-6-mercapto-, chloride (1:1) Formula
153851-71-9
-
Cefminox Formula
75481-73-1
-
Clindamycin Formula
18323-44-9
-
Bacitracin Zinc Structure
1405-89-6
-
Spectinomycin hydrochloride Structure
21736-83-4
-
What is Isoconazole nitrate
24168-96-5
-
What is α-Solanine
20562-02-1